Articles dans des revues avec comité de lecture (22)
  1. 1. Chung, F. F.-L., Maldonado, S. G., Nemc, A., Bouaoun, L., Cahais, V., Cuenin, C., Salle, A., Johnson, T., Ergüner, B., Laplana, M., Datlinger, P., Jeschke, J., Weiderpass, E., Kristensen, V., Delaloge, S., Fuks, F., Risch, A., Ghantous, A., Plass, C., Bock, C., Kaaks, R., & Herceg, Z. (2023). Buffy coat signatures of breast cancer risk in a prospective cohort study. Clinical Epigenetics, 15(1), 102. doi:10.1186/s13148-023-01509-6
  2. 2. Jeschke, J. (2023). Editorial: Advances in cancer detection and diagnosis: from liquid biopsies and molecular biomarkers to opportunistic intratumoral bacteria. Current opinion in oncology, 35(2), 114. doi:10.1097/CCO.0000000000000930
  3. 3. Penning, A., Jeschke, J., & Fuks, F. (2022). Why novel mRNA modifications are so challenging and what we can do about it. Nature reviews. Molecular cell biology, 23(6), 385-386. doi:10.1038/s41580-022-00485-8
  4. 4. Jeschke, J., Collignon, E., Al Wardi, C., Krayem, M., Bizet, M., Jia, Y., Garaud, S., Wimana, Z., Calonne, E., Hassabi, B., Morandini, R., Deplus, R., Putmans, P., Dube, G., Singh, N. K., Koch, A., Shostak, K., Rizzotto, L., Ross, R. L., Desmedt, C., Bareche, Y., Rothé, F., Lehmann-Che, J., Duterque-Coquillaud, M., Leroy, X., Menschaert, G., Teixeira, L., Guo, M., Limbach, P. A., Close, P., Chariot, A., Leucci, E., Ghanem, G., Yuan, B., Willard-Gallo, K., Sotiriou, C., Marine, J.-C., & Fuks, F. (2021). Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors. Nature Cancer, 2(6), 611-628. doi:10.1038/s43018-021-00223-7
  5. 5. Koch, A., Jeschke, J., Van Criekinge, W., van Engeland, M., & De Meyer, T. (2019). MEXPRESS update 2019. Nucleic acids research, 47(W1), W561-W565. doi:10.1093/nar/gkz445
  6. 6. Jeschke, J., Bizet, M., Desmedt, C., Calonne, E., Dedeurwaerder, S., Garaud, S., Koch, A., Larsimont, D., Salgado, R., Van den Eynden, G., Willard-Gallo, K., Bontempi, G., Defrance, M., Sotiriou, C., & Fuks, F. (2017). DNA methylation-based immune response signature improves patient diagnosis in multiple cancers. The Journal of clinical investigation, 127(8), 3090-3102. doi:10.1172/JCI91095
  7. 7. Van Vlodrop, I. J. H., Joosten, S. C., De Meyer, T., Smits, K. M., Van Neste, L., Melotte, V., Baldewijns, M. M. L. L. M., Schouten, L. J., van den Brandt, P. A., Jeschke, J., Yi, J. M., Schuebel, K. K., Ahuja, N., Herman, J. G., Aarts, M. J., Bosman, F. T., Van Criekinge, W., & van Engeland, M. (2017). A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients. Clinical cancer research, 23(8), 2006-2018. doi:10.1158/1078-0432.CCR-16-1236
  8. 8. Siebenkäs, C., Chiappinelli, K. K., Guzzetta, A. A., Sharma, A., Jeschke, J., Vatapalli, R., Baylin, S. B., & Ahuja, N. (2017). Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. PloS one, 12(6), e0179501. doi:10.1371/journal.pone.0179501
  9. 9. Jeschke, J., Collignon, E., & Fuks, F. (2016). Portraits of TET-mediated DNA hydroxymethylation in cancer. Current opinion in genetics & development, 36, 16-26. doi:10.1016/j.gde.2016.01.004
  10. 10. Koch, A., De Meyer, T., Jeschke, J., & Van Criekinge, W. (2015). MEXPRESS: Visualizing expression, DNA methylation and clinical TCGA data. BMC genomics, 16(1), 636. doi:10.1186/s12864-015-1847-z
  11. 11. Delatte, B., Jeschke, J., Defrance, M., Bachman, M., Creppe, C., Calonne, E., Bizet, M., Deplus, R., Marroquí, L., Libin, M., Ravichandran, M., Mascart, F., Eizirik, D. L., Murrell, A., Jurkowski, T. P., & Fuks, F. (2015). Genome-wide hydroxymethylcytosine pattern changes in response to oxidative stress. Scientific reports, 5, 12714. doi:10.1038/srep12714
  12. 12. Deckers, I. A. G., Schouten, L. L., Van Neste, L., Van Vlodrop, I. J. H., Soetekouw, P. M. M. B. P., Baldewijns, M. M. L. L. M., Jeschke, J., Ahuja, N., Herman, J. G., Van Den Brandt, P. P., & van Engeland, M. (2015). Promoter methylation of CDO1 identifies clear-cell renal cell cancer patients with poor survival outcome. Clinical cancer research, 21(15), 3492-3500. doi:10.1158/1078-0432.CCR-14-2049
    13. << Précédent 1 2 3 Suivant >>